Weiss Ratings Reaffirms “Sell (D-)” Rating for Rezolute (NASDAQ:RZLT)

Rezolute (NASDAQ:RZLT)‘s stock had its “sell (d-)” rating reissued by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other research analysts also recently issued reports on the company. Wedbush reiterated an “outperform” rating and set a $12.00 price objective on shares of Rezolute in a research note on Thursday, September 18th. BTIG Research restated a “buy” rating and issued a $17.00 price target on shares of Rezolute in a research note on Thursday, September 18th. Maxim Group upped their price target on Rezolute from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research note on Wednesday, September 3rd. Finally, Guggenheim restated a “buy” rating and issued a $15.00 price target on shares of Rezolute in a research note on Monday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Rezolute presently has a consensus rating of “Moderate Buy” and an average target price of $14.50.

Rezolute Stock Performance

Shares of NASDAQ:RZLT opened at $8.72 on Wednesday. Rezolute has a fifty-two week low of $2.21 and a fifty-two week high of $9.72. The firm has a market cap of $791.86 million, a price-to-earnings ratio of -8.99 and a beta of 0.04. The business has a 50-day simple moving average of $7.47 and a two-hundred day simple moving average of $5.21.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings results on Wednesday, September 17th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.03). As a group, research analysts predict that Rezolute will post -0.93 earnings per share for the current year.

Institutional Trading of Rezolute

Several hedge funds have recently modified their holdings of the company. Rosalind Advisors Inc. purchased a new stake in Rezolute during the 2nd quarter valued at $7,766,000. Opaleye Management Inc. raised its holdings in Rezolute by 94.3% during the 2nd quarter. Opaleye Management Inc. now owns 903,442 shares of the company’s stock valued at $4,029,000 after buying an additional 438,442 shares during the period. Massar Capital Management LP purchased a new stake in Rezolute during the 2nd quarter valued at $126,000. BNP Paribas Financial Markets purchased a new stake in Rezolute during the 2nd quarter valued at $25,000. Finally, Boothbay Fund Management LLC raised its holdings in Rezolute by 1,745.6% during the 2nd quarter. Boothbay Fund Management LLC now owns 266,671 shares of the company’s stock valued at $1,189,000 after buying an additional 252,222 shares during the period. 82.97% of the stock is owned by hedge funds and other institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.